Evidence map›Paper›PMID 41993588›Full record

ArticleFrontiers in pharmacology2026

Single-cell and spatial dissection of IGF2BP3-driven endothelial reprogramming underlying microvascular invasion in hepatocellular carcinoma.

Xinglong Zhang, Huarong Fu, Jun Lu

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinglong ZhangDepartment of Oncology, Anhui Zhongke Gengjiu Hospital, Hefei, Anhui, China.
Huarong FuDepartment of Oncology, Anhui Zhongke Gengjiu Hospital, Hefei, Anhui, China.
Jun LuDepartment of Oncology, Anhui Zhongke Gengjiu Hospital, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Microvascular invasion (MVI) is a critical determinant of early recurrence and poor prognosis in hepatocellular carcinoma (HCC). The cellular and molecular mechanisms driving MVI, particularly the role of endothelial heterogeneity, remain incompletely understood. Methods: We integrated single-cell and spatial transcriptomics from multiple HCC cohorts to identify MVI-associated endothelial subpopulations. GeneNMF and hdWGCNA were applied to define stable gene modules, while CellChat and NicheNet analyzed intercellular signaling. Prognostic relevance was assessed using machine learning-based risk models across TCGA-LIHC and external datasets. Functional assays including EdU proliferation, tube formation, and Western blot were conducted to validate the role of IGF2BP3 in tumor-associated endothelial cells. Results: We identified a distinct MVI-associated endothelial subpopulation (MVI Endo) enriched in pro-angiogenic, EMT-like, and TGF-β-responsive pathways, predominantly localized near tumor vasculature. MVI Endo engaged in robust VEGF, ANGPT2, and TGF-β signaling with tumor and stromal cells. Machine learning-derived prognostic models highlighted IGF2BP3 as a central regulator, and functional assays demonstrated that IGF2BP3 enhances endothelial proliferation and tube formation via upregulation of VEGF-A and ANGPT2, supporting its involvement in the vascular phenotype associated with MVI. Conclusion: This study characterizes the endothelial landscape associated with MVI, implicates IGF2BP3 as a critical regulator of vascular reprogramming, and provides a foundation for precision vascular-targeted therapies in HCC.

Indexed as

drug targetsendothelial heterogeneityhepatocellular carcinomaIGF2BP3microvascular invasion

Identifiers

PMID41993588
PMCPMC13079049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.